Oncotarget

Research Papers:

Chaperonin containing TCP1 subunit 5 is a tumor associated antigen of non-small cell lung cancer

Hongjun Gao _, Min Zheng, Sijin Sun, Hongwu Wang, Zhigang Yue, Yun Zhu, Xiaochen Han, Junquan Yang, Yanqiu Zhou, Yiran Cai and Wanning Hu

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:64170-64179. https://doi.org/10.18632/oncotarget.19369

Metrics: PDF 1767 views  |   HTML 3253 views  |   ?  


Abstract

Hongjun Gao1,*, Min Zheng2,*, Sijin Sun5,*, Hongwu Wang3, Zhigang Yue1, Yun Zhu1, Xiaochen Han2, Junquan Yang2, Yanqiu Zhou1,3, Yiran Cai4 and Wanning Hu2

1Department of Clinical Laboratory, China Meitan General Hospital, Beijing, PR China

2Department of Oncology, Tangshan People’s Hospital & Tangshan Cancer Hospital, North China University of Science and Technology, Tangshan, PR China

3Department of Oncology, China Meitan General Hospital, Beijing, PR China

4Department of Pathology, Beijing Chest Hospital, Capital Medical University & Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, PR China

5Department of Clinical Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, PR China

*These authors have contributed equally to this work

Correspondence to:

Hongjun Gao, email: [email protected]

Yanqiu Zhou, email: [email protected]

Wanning Hu, email: [email protected]

Yiran Cai, email: [email protected]

Keywords: CCT5, non-small cell lung cancer, CEA, CYFRA 21-1

Received: February 24, 2017    Accepted: June 18, 2017    Published: July 18, 2017

ABSTRACT

Novel tumor antigens and their related autoantibodies have tremendous potential for early diagnosis of non-small cell lung cancer (NSCLC). In this study, we identify antigens from NSCLC tissue and autoantibodies in sera of patients with NSCLC using a modified proteomics-based approach. We seperated and identified four NSCLC-associated proteins extracted from the cytosol in tumor tissues by mini-two-dimensional gel electrophoresis, followed by Western blot and hybridization with individual sera for confirmation of antibody binding. Of the proteins we identified, we selected 58 kDa chaperonin containing TCP1(T-Complex Protein 1) subunit 5 (CCT5) for validation. Serum levels of carcinoembryonic antigen (CEA) and cytokeratin 19 fragments (CYFRA 21-1) were measured in all serum samples with an immunoluminometric assay and a receiver operating characteristic (ROC) curve was analyzed for autoantibodies against CCT5, CEA and CYFRA 21-1. The results show that CCT5 can induce an autoantibody response in NSCLC sera and show higher expression in NSCLC tissues by immunohistochemistry and Western blot. Anti-CCT5 autoantibody was found in 51% (23/45) of patients with NSCLC, but only 2.5% (1/40) in non-tumor individual controls. A receiver operating characteristic curve constructed with a panel of autoantibodies against CCT5 (AUC=0.749), CEA (AUC=0.6758), and CYFRA 21-1(AUC=0.760) show a sensitivity of 51.1% and 97.5% specificity in discriminating NSCLC from matched controls. These results indicate the potential utility of screening autoantibodies in sera, show that CCT5 could be used as a biomarker in cancer diagnosis.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19369